• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Johnson & Johnson (JnJ) (Group)

Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 250 Johnson & Johnson operating companies employ approximately 121,000 men and women in 57 countries and sell products throughout the world. *

 

	Start	1888-01-01 established?
	Industry	pharmaceutical
	Industry 2	diagnostics (medical/biological)
	Street	One Johnson & Johnson Plaza
	City	08933 New Brunswick, NJ
		Address record changed: 2020-12-02
Basic data	Employees	J: more than 100,0 (2017-01-26)
	Currency	USD
	Annual sales	61,095,000,000 (sales, consolidated (2007) 2007-12-31)
	Profit	10,576,000,000 (2007-12-31)
	Cash	16,055,000,000 (2005-12-31)
		* Document for �About Section�:
		Record changed: 2020-08-19

Advertisement

More documents for Johnson & Johnson (JnJ) (Group)

• [1] Argenx SE. (6/7/21). "Press Release: Argenx to Regain Global Rights to Cusatuzumab". Breda....
• [2] Nouscom AG. (12/11/20). "Press Release: Nouscom Appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer". Basel....
• [3] MorphoSys AG. (12/2/20). "Press Release: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)". Planegg....
• [4] BaseLaunch (BaselArea.swiss). (9/28/20). "Press Release: BaseLaunch Announces that Johnson & Johnson Innovation Has Renewed Its Commitment Becoming Latest Strategic Partner in the Second Phase". Basel....
• [5] Bavarian Nordic A/S. (6/12/20). "Press Release: Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen". Copenhagen....
• [6] Lava Therapeutics B.V.. (5/15/20). "Press Release: Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager Therapeutics". Utrecht....
• [7] Genmab A/S. (12/13/19). "Press Release: CHMP Issues Positive Opinion Recommending Darzalex (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma". Copenhagen....
• [8] Actimed Therapeutics Ltd.. (10/30/19). "Press Release: Actimed Therapeutics Appoints Robin Bhattacherjee as CEO". Ascot....
• [9] MorphoSys AG. (9/16/19). "Press Release: MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis". Planegg....
• [10] MeiraGTx Holdings plc. (8/7/19). "Press Release: MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update". London & New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.